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Abstract 
Epithelial cancers including breast and prostate commonly progress to form 
incurable bone metastases. For this to occur cancer cells must adapt their 
phenotype and behaviour to enable detachment from the primary tumour, 
invasion into the vasculature, homing to and subsequent colonisation of bone.  
It is widely accepted that the metastatic process is driven by the 
transformation of cancer cells from a sessile epithelial to a motile 
mesenchymal phenotype through epithelial-mesenchymal transition (EMT). 
Dissemination of these motile cells into the circulation provides the conduit for 
cells to metastasise to distant organs. However, accumulating evidence 
suggests that EMT is not sufficient for metastasis to occur and specific tissue 
homing factors are required for tumour cells to lodge and grow in bone. Once 
tumour cells are disseminated in the bone environment they can revert back 
into an epithelial phenotype through the reverse process of mesenchymal-
epithelial transition (MET) and form secondary tumours. In this review we 
describe the molecular alterations undertaken by breast cancer cells at each 
stage of the metastatic cascade and discuss how these changes facilitate 
bone metastasis. 
 
Introduction 
Breast cancer is the most frequently diagnosed cancer and leading cause of 
cancer death in females worldwide1. Despite this, the majority of primary 
tumours that remain confined to the breast are amenable to currently 
available treatments and 5-year survival rates for patients with non-metastatic 
disease is ~93%. However, once the tumour has metastasised to a distant 
site 5-year survival decreases to ~22% (National Cancer Institute SEER 
database). For breast cancer the most common site of metastasis is bone and 
patients with this condition have a median survival of around 2-3 years 
following initial diagnosis of bone involvement. Identification of new 
therapeutic approaches are therefore needed to improve outcome for patients 
with tumour spread to the skeleton. A better understanding of the molecular 
determinants that drive the different stages of breast cancer metastasis to 
bone are essential for the future development of successful therapeutic 
strategies. 
Metastatic conversion of breast cancer cells is driven by genetic and 
phenotypic adaptations that change tumour cells from an epithelial to a 
mesenchymal phenotype (EMT). This process is initiated by the 
overexpression of mesenchymal proteins such as fibronectin and 
metalloproteinases2-3 in addition to the loss of cell adhesion molecules 
including E-cadherin and B-cadherin. Loss of E-cadherin is thought to be 
fundamental in this process resulting in reduced adhesion of epithelial cells to 
desmosomes, increased cellular motility and dissemination of tumour cells 
into the circulation4. Once in the circulation tumour cells must home to a 
secondary environment where they will only be capable of forming 
metastases if the environment is appropriate5. On homing to bone it is thought 
that tumour cells occupy specific niches that are identical to, or overlapping 
with, the hematopoietic stem cell niche6-7. This niche is made up of two 
primary cell types: stromal cells and transient cells. Stromal cells include 
adipocytes, fibroblasts and osteoblasts and these originate from 
mesenchymal cells in the marrow. These cells contribute to the proliferation 
and differentiation of cancer cells via the secretion of molecules such as 
vascular cell adhesion molecule 1, syndecan-1 and matrix metalloproteinase 
2 (MMP2)8. Transient cells include T cells, erythrocytes and platelets, all of 
which have been shown to stimulate tumour growth and metastasis9. 
Furthermore, the continuous process of bone remodelling, involving 
osteoclast mediated bone resorption resulting in the release of a multitude of 
growth factors, cytokines and cell adhesion molecules from the bone matrix 
making bone an attractive site for metastatic tumour cells10-11. 
The interactions between tumour cells and their microenvironment are 
important regulators of cancer metastasis and many excellent reviews have 
been published on this subject10,12-13. However, increasing evidence suggests 
that metastasis occurs as a result of a stepwise accumulation of genetic 
mutations, with different molecular alterations being required for different 
stages in the metastatic process. In the current review we focus on the 
molecular alterations that drive the different stages of metastasis: tumour cell 
invasion and dissemination into the circulation, tumour cell homing to bone, 
and tumour cell colonisation and growth in the metastatic site (bone). 
 
Tumour cell Invasion and dissemination into the circulation. 
Amassing evidence shows that cells escaping primary tumours and becoming 
disseminated into the circulation have a mesenchymal phenotype and it is 
widely accepted that these cells originate from a subset of primary tumour 
cells that have undergone EMT. The exact molecular mechanisms that dictate 
EMT in tumour cells remain enigmatic, however studies of EMT that occur 
during developmental processes such as gastrulation and neural crest 
delamination provide clues as to how EMT may occur in metastasis14. 
Currently EMT is divided into three separate subtypes associated with distinct 
biological functions: 
1) Implantation of embryogenesis and organ development. 
2) Tissue regeneration and organ fibrosis and wound healing process, 
3) Cancer progression and metastasis. 
The induction of type 3 EMT at the onset of metastasis is facilitated by genetic 
alterations acquired by cancer cells and these generate cells with invasive 
properties that enable them to move into the blood stream (figure 1). In this 
review we will discuss the key transcriptional and cellular molecules that 
coordinate to drive EMT (as shown in figure 2). We will describe experimental 
evidence for new emerging concepts that challenge some current hypothesis 
to establish an up to date functional role for EMT mediators in the facilitation 
of tumour cell escape from the primary tumour and dissemination into the 
circulation. 
The Transforming Growth Factor (TGF)-β superfamily 
Members of the TGF-β superfamily including Bone Morphogenic Proteins 
(BMPs) and TGF-β, influence EMT via regulation of transcription factors SIP1, 
slug and Snail which in turn supress the adhesion molecule E-cadherin 
causing loss of cell-cell adhesion15. 
Experimental evidence from murine mammary cancer 4T1 cells highlight the 
critical early role that TGF-β plays in inducing EMT. Cells treated with TGF-β 
acquired a spindle-like morphology and expression of the mesenchymal 
markers N-cadherin and vimentin. These changes were not seen when the 
cells were treated simultaneously with TGF-β and the TGF-β antagonist 
Schisandrin B (SchB). In addition, treatment of mice bearing 4T1 cells in a 
mammary fat pad with SchB resulted in significant suppression of metastasis 
to bone and lung but did not affect tumour growth at the primary site. 
Furthermore TGF-β appears to be specific to early events associated with 
tumour cell dissemination into the circulation as SchB did not inhibit lung 
metastasis when 4T1 cells were injected into the tail vein16. 
TGF-β activity is controlled by expression of BMP7 and up-regulation of 
BMP7 in vitro counteracts physiological EMT via inhibition of SMAD mediated 
TGF-β signalling and decreased expression of vimentin. In agreement with 
this BMP7 expression has been shown to be inversely proportional to the 
tumourgenisity and invasive behaviour of MDA-MB-231 breast cancer cells17-
18. However, expression of BMP7 in primary tumour biopsies appears to 
contradict this finding. In a clinical setting, high levels of BMP7 expression in 
primary tumours has been strongly associated with accelerated bone 
metastasis, especially from ductal carcinomas19. Therefore the role of BMP7 
in EMT remains inconclusive. 
TWIST 
The role of TWIST as a master regulator of type 1 EMT is well documented 20-
22. In addition to this there is a considerable amount of evidence suggesting 
that TWIST also plays a key role in type 3 EMT and metastasisreviewed in 23-24. 
TWIST is expressed in a variety of invasive and metastatic breast cancer cells 
including mouse 4T1 cells and human SUM1315, MDA-MB-231 and MDA-
MB-435 cells. In contrast, this gene is not expressed on non-metastatic MDA-
MB-436, MCF7 and BT20. siRNA knockdown of TWIST in 4T1 cells 
significantly reduces lung metastasis in vivo and numbers of tumour cells 
shed into the circulation, without altering primary tumour growth25. The role of 
TWIST in stimulating EMT is further evident from experiments carried out in 
human mammary epithelial cells in which retroviral transfection with TWIST 
resulted in loss of cell-cell contact with elevated expression of vimentin, α-
smooth muscle actin and N-cadherin as well as loss of E-cadherin, α-catenin, 
β-catenin and δ-catenin from the cell membrane25. Laboratory studies 
demonstrating TWIST activity induces metastasis has been extensively 
confirmed in clinical samples. Microarray analysis of different breast cancer 
subtypes revealed that TWIST is expresses by 70% of invasive lobular 
carcinomas and that tumour samples expressing TWIST also demonstrated 
other features of having undergone EMT including almost universal loss of E-
cadherin (97%)25. Overall, data suggest that TWIST induces EMT by down-
regulating E-cadherin mediated cell-cell adhesion in epithelial cells. 
HIF-1α 
It has been hypothesised that tumour cells undergo EMT in response to 
unfavourable conditions such as hypoxia in order to allow them to move to an 
environment that will better support their growth26. Evidence from in vitro 
studies using MCF7 cells show that hypoxia induced HIF-1α drives EMT and 
onset of metastasis via direct regulation of TWIST expression27-28. Under 
hypoxic conditions HIF-1α binds directly to the hypoxia response element of 
the TWIST promoter leading to increased expression of TWIST. This in turn 
results in upregulation of VEGF and the formation of new blood vessels, a 
subsequent increase in E-cadherin followed by loss of vimentin and N-
cadherin. This process of hypoxia induced EMT can be completely reversed 
by inhibiting HIF-1α with siRNA implying that HIF-1α is a key regulator of 
EMT27. It therefore appears that hypoxia drives onset of metastasis by 
inducing HIF-1α and TWIST signalling arming the cells with a repertoire of 
molecules enabling escape from the local microenvironment into the 
circulation. 
E-cadherin 
Expression of E-cadherin has become a hallmark of many EMT assays and it 
is generally accepted that loss of this molecule is critical for the initial escape 
and migration of individual cells from the primary tumour site29. E-cadherin is 
a single span transmembrane glycoprotein that interacts with ϒ-catenin in 
adjacent cells to form intercellular adhesion junctions30. Loss of E-cadherin 
disrupts cell-cell contact, leading to loss of the apical-basal barrier and cellular 
polarity, allowing growth factors that would normally have been segregated 
from the basolateral surface to interact with receptors in an autocrine fashion 
and further drive the EMT phenotype31. The critical role of E-cadherin in EMT 
and metastasis is well documented2-3. Reduced expression of this molecule in 
non-metastatic human mammary cell lines (HMLE) with shRNA results in loss 
of cell-to-cell contact and an increase in markers of mesenchymal cells. 
Furthermore, orthotopic injection of E-cadherin knockdown HMLE cells into 
the mammary fat pad of nude mice resulted in significantly more micro-and 
macro-metastases in the lungs compared with mice injected with control 
HMLE cells32. 
Loss of E-cadherin has generally been considered as being pivotal for the 
onset of metastasis, however, emerging evidence suggests that cell-to-cell 
contact is the critical key to metastasis and that disrupting this process can 
induce metastasis without altering E-cadherin. Plakoglobin is the gene that 
encodes the Υ-catenin protein, which links E-cadherin to the actin 
cytoskeleton33. Knockdown of plakoglobin by miRNA in MCF7 and T47D 
breast cancer cells leads to loss of cell-cell contact and increased tumour cell 
invasion. Furthermore, implanting plakoglobin knockdown cells into mammary 
fat pads of nude mice resulted in increased shedding of tumour cells into the 
blood stream compared with animals injected with control cells34. Importantly, 
reduced plakoglobin expression resulted in an 80% reduction in Υ-catenin, but 
did not alter E-cadherin expression or location of the cell membrane. 
Interestingly, however, decreased plakoglobin was found to reduce NM23-H1 
(encoding nucleoside diphosphate kinase A, metastasis suppressor) that 
disrupts cell-cell adhesion via α-and β-catenin. Plakoglobin has been shown 
to promote α and β catenin nuclear translocation34 implying that increased 
metastatic capability of cells can be driven independently of E-cadherin 
expression by loss of plakoglobin and NM23-H1. 
Mucins 
Aberrant expression of the transmembrane glycoproteins MUC1 and MUC4 a 
have all been associated with invasive epithelial carcinomas including breast. 
Recent evidence is emerging for a role of these proteins in EMT and 
metastasis. Experiments using an in vitro model of mouse mammary tumour 
cells (DA3) have demonstrated that overexpression of truncated human 
MUC1 leads to EMT, associated with ERK1/2 dependent activation of 
fibronectin and an increase in cell invasion35. Furthermore, in prostate cancer 
cells the cytoplasmic tail of MUC1 has been shown to interact with the DNA 
binding domain of androgen receptor, resulting in activation of EMT and 
increased invasiveness of cancer cells36. Direct evidence for an association 
between MUC1 and initiation of EMT in cancer has been shown in a mouse 
model of pancreatic ductal adenocarcinoma. Overexpression of MUC1 led to 
elevated levels of vimentin, slug and snail compared with levels in mutant 
MUC1 (MUC1 CT) mice. In addition, MUC1 in MUC CT mice did not 
immunoprecipitate with or cause nuclear translocation of β-catenin, thereby 
blocking the transcription of genes associated with EMT37. 
Studies utilising models of triple negative breast cancer have shown that 
MUC4 mucin enhances the invasive and migratory potential of cancer cells 
through upregulation of EGFR family proteins. A separate study demonstrated 
that knockdown of MUC4 in breast cancer cells leads to molecular and 
biochemical alterations that are necessary for EMT including reduced 
expression of mesenchymal markers such as vimentin and vitronectin and 
increased expression of the epithelial marker cytokeratin 1838. These data 
suggest that MUC4 plays an important role in EMT, transforming breast 
cancer cells into a more migratory and aggressive phenotype. 
Cytokeratins 8, 18 and 19 
Cytokeratins are the protein components of intermediate filaments that make 
up the supporting scaffolding within cells. The organisation and expression of 
these proteins change as epithelial cells gradually adopt an epithelial 
phenotype39. The change in expression profile of cytokeratins during EMT 
provides insight into how changes in structural integrity of cancer cells can 
drive invasion during cancer progression. In human breast cancer cells, 
expression of cytokeratins K8 and K18 and 19 correlate with invasive potential, 
with high levels of K8 and K18 expressed in less invasive MCF7 compared 
with more invasive MDA-MB-231 and MDA-MB-436 cells and K19 being 
undetectable in invasive cells. Conversely, a negative correlation was seen 
between K8, K18 and K19 and filament proteins with increased vimentin and 
fibronectin observed in MDA-MB-231 and MDA-MB-436 compared with 
MCF740.  
Direct evidence supporting an active role of cytokeratins in metastasis has 
come from a recent study that used shRNA to knock down K8 and K18 in 
epithelial cancer cells, hepatocellular carcinoma (EppG2) and cervical 
carcinoma (HeLa). Reduced expression of K8 and K18 in these cells led to 
hyperactivity of PI3K, NF-KB and Akt as well as increased expression of 
MMP2 and MMP9. Although it is recognised that K8 and K18 are involved in 
intracellular signalling and that these molecules are specific to epithelial cells, 
loss of these markers does not modify other markers of EMT. Instead, K8 and 
K18 are modulated by claudin-1 that influences the phenotype of epithelial 
cells independently of other EMT markers41. Therefore, it is likely that in 
addition to loss of K8 and K18 being a hallmark of EMT, modulation of these 
proteins at the transcriptional level influences cancer cell phenotype by 
orchestrating structural alterations that enable cells to escape from the 
primary tumour. 
Fibronectin 
The extra cellular matrix protein fibronectin plays a critical role in cellular 
adhesion, migration and transformation through activating the PI3/Akt 
pathway when bound to αvβ1 integrin
42. Normal adult breast tissue is largely 
devoid of Fibronectin, however, during the process of tumourigenesis levels of 
this protein increase in the stroma with highest levels of expression detected 
at the invasive front of tumours during EMT42. In vitro evidence from human 
mammary breast cancer cells, MCF-10A, have highlighted a role for 
Fibronectin in promoting onset of EMT. Exposure of MCF-10A cells to 
exogenous Fibronectin stimulated cell migration and induced an EMT 
response including upregulation of the EMT markers Fibronectin Snail, N-
cadherin, vimentin, MMP2, α-smooth muscle actin and phospho-Smad2. In 
addition, exogenous Fibronectin is able to induce EMT under serum-free 
conditions; this process could be reversed following addition of a TGFβ 
neutralising antibody43. These data suggesting that Fibronectin is able to 
induce EMT in breast cancers via enhancing the activity of endogenous TGFβ. 
Vimentin 
The functional role of vimentin in EMT is yet to be fully elucidated, however, 
high levels of expression of this molecule are associated with an increased 
met static phenotype. Overexpression of vimentin in MCF7 breast cancer cells 
results in increased motility, whereas knocking down vimentin expression with 
siRNA in MDA-MB-231 cells down regulates genes associated with an 
invasive phenotype, Axl, ITGB4 and PLAU, and upregulates normal mammary 
epithelial genes, REAB25 and EHF44. Under non-cancerous conditions 
vimentin is involved in processes that require cell migration such as wound 
healing where it plays a pivotal role in determining cell polarity, regulation of 
cell to cell contact and transport of signalling proteins45. It therefore seems 
likely that altered expression of this molecule in cancerous tissue may also 
affect cell-cell adhesion and cell polarity enabling cells to detach from the 
primary tumour and invade the surrounding stroma. 
 
Tumour cell homing to bone 
Following degradation of the extracellular matrix tumour cells cross the 
basement membrane and enter the circulation cancer cells. Once in the blood 
and/or lymphatic systems tumour cells must home and disseminate to a 
secondary site where the microenvironment is favourable for them to 
proliferate and establish metastases. In theory, breast cancer cells can 
metastasize to any organ of the body, however, it has been demonstrated that 
breast cancer cells prefer to home to certain organs such as bone, lungs, liver 
and brain5-6. Even though the exact mechanism of the metastasis of breast 
cancer cells to these specific sites is still not completely understood. In 1889 
Stephen Paget proposed that both cancer cells (seed) and the secondary 
sites (soil) facilitate the process by releasing factors, signals and molecules 
that make the microenvironment appropriate and increase the probability of 
cancer cells to grow there (‘’seed and soil hypothesis’’)46, this hypothesis still 
appears to hold today and molecules involved in the process of bone homing 
are shown in figure 3.  
Chemokines 
One group of molecules that have been shown to play a crucial role in organ-
specific metastasis of breast cancer cells are the chemokines and their 
receptors (G-protein couple receptors). The role of chemokines in organ-
specific homing was first demonstrated in homing of lymphocytes and 
hematopoietic cells to different organs47. Studies have shown that breast 
cancer cells express these molecules leading to the hypothesis that they 
function as homing factors for breast cancer metastasis48-49. More specifically, 
the chemokine receptors CCR7 and CXCR4 were found to be upregulated in 
metastatic breast cancer cell lines as well as in primary breast tumours that 
metastasise49. Moreover, higher levels of their respective ligands 
CCL21/6Ckine and CXCL12/SDF-1a were found in sites that breast cancer 
cells preferentially migrate to such as bone, lung, liver and lymph nodes, 
compared with lower levels in small intestine and kidney which are sites that 
breast cancer cells rarely metastasise49-50. CXCR4 has been shown to 
specifically promote bone metastasis by stimulating tumour cell recruitment 
and homing to bone in response to its interaction with CXCL12/SDF-1a 
ligand51. Furthermore, inhibition of CXCL12/CXCR4 interaction using 
neutralizing antibodies or RNA resulted in reduced breast tumour growth as 
well reduced cell migration, invasion and metastasis49, 52-53. The role of 
CXCR4 in breast cancer cell homing to bone has further been demonstrated 
by genetic analysis of bone homing MDA-MB-231, non-bone homing MDA-
MB-231 breast cancer cells and normal human mammary epithelium 
(MCF10A). In these experiments bone homing cells expressed significantly 
more CXCR4 compared with their parental clone and normal mammary 
epithelium and this overexpression was associated with higher number of 
bone metastases in vivo2.  However, it should be noted that expression of 
CXCR4 is not a universal feature in breast cancer bone homing. We and 
others have generated bone homing clones of MDA-MB-231 cells (BO2 and 
MDA-IV cells) using the same method as described by Kang et al2,54-55. 
Interestingly, CXCR4 was not detected in either of these bone homing cell 
lines by microarray or PCR analysis. 
Intergrins 
Intergrins are cell surface glycoproteins that facilitate cell-cell and cell-
extracellular matrix adhesion and cell migrationReviewed in 56. Expression of 
these molecules on both tumour cells in bone and the supporting host stromal 
cells (osteoclasts, new blood vessels, inflammatory cells, platelets and bone 
marrow stromal cells) play key roles in enhancing bone metastasis. There are 
8 beta and 18 alpha integrin subunits that can make up 24 different 
combinations in different cell types, each characterised by distinct ligand 
binding specificities, signalling abilities and regulatory mechanismsReviewed in 57. 
Metastatic tumour cells show differential integrin heterodimerisation and 
activation compared with non-metastatic tumour cells that enable cells to 
home and colonise specific metastatic sites58. In bone metastasis the β1 and 
β3 family members appear to be of major importance.  
In breast cancer αvβ3 is increased in expression in bone metastatic cells 
compared with non-metastatic cells59. Binding of αvβ3 integrin to bone 
extracellular matrix proteins including osteopontin, vitronectin and bone sialo-
protein promote adhesion of breast cancer cells to bone60. Therefore it is 
likely that breast cancer cells expressing integrins that can interact with such 
proteins are more likely to home to bone. In 2002 Pecheur and co-workers 
showed that expression of αvβ3 integrin by breast cancer cells increased 
adhesion of cancer cells to bone and the incidence of bone metastasis61. 
Moreover, inhibition of αvβ3 integrin using a small molecule antagonist 
suppresses breast cancer bone metastasis indicating an explicit role for αvβ3 
integrin in bone-specific homing62.  The β1 family member, α5β1, specifically 
binds to fibronectin on human bone marrow stroma and expression of this 
molecule on breast cancer cells facilitates interaction with the bone stroma. 
The interaction between tumour cell α5β1 and host stromal cell fibronectin 
appears to contribute to the survival of growth arrested breast cancer cells, a 
potential mechanism through which tumour cells can become sequestered 
and dormant within the bone marrow cavity and may later begin to proliferate 
and establish skeletal metastases63. 
 
Additional molecules associated with bone homing 
In addition to chemokines and intergrins a multitude of other molecules have 
been shown to play important roles in chemotaxis of breast cancer cells to 
bone (see figure 2): Increased expression of MMP-1, interleukin 11 (IL-11) 
and connective tissue factor (CTGF) have been identified in bone homing 
clones of MDA-MB-231 breast cancer cells compared with parental cells in 
vivo2. Using a similar approach in which bone homing clones of MDA-MB-231 
cells were compared with parental cells we and others have found that  bone 
homong is associated with decreased cell-cell adhesion and migration, 
coupled with significantly reduced levels of the cell adhesion molecule 
fibronectin and calcium signal binding protein S100A454-55. Interestingly, we 
also found a strong link between IL-1B expression and bone homing in both 
MDA-MB-231 cells and primary tumours from breast cancer patients 
indicating that this molecule may promote an invasive and motile phenotype in 
breast cancer cells55.  
 
Tumour cell colonisation and growth to bone 
Tumour cells are disseminated into the bone environment via the blood 
stream and as a result the most common homing site is the highly 
vascularised metaphysis in the long bones. Once in the bone 
microenvironment it is hypothesised that breast cancer cells compete for the 
hematopoietic stem cell (HSCs) niche and once within this niche they can be 
stimulated to proliferate55, 64. In addition to molecules with well defined roles in 
bone colonisation, discussed below, we have previously demonstrated that 
this process is also associated with increased levels of MMP9, HRAS and 
fibronectin55. MMP9 has strong associations with increased tumour cell 
invasion in a number of cancer types65 and increased MMP9 expression has 
been shown to increase the capacity of tumour cells to extravasate as well as 
to cause activation of bone resorbing osteoclasts66-67. In addition to the pro 
invasive properties of MMP9 HRAS over-expression has been shown to 
increase invasion of MCF10A breast cells and to transform these from an 
endothelial to an epithelial cell type (MET)68. Fibronectin on the other hand 
has well characterised properties as a cell adhesion molecule and has been 
shown to be upregulated in bone metastatic deposits compared with primary 
breast tumours69. It is therefore likely that increased expression of fibronectin 
enables tumour cells to adhere to the HSC niche once they have successfully 
entered the bone microenvironment60, 70. 
Mesenchymal to Epithelial transition and bone colonisation 
To enable colonisation of bone, tumour cells undergo a reverse EMT 
transition known as Mesenchymal-Epithelial transition (MET), reactivating 
their epithelial cell properties and increasing their adhesion and interactions 
with the bone marrow microenvironment71-72 (Figure 3). The re-expression of 
E-cadherin is considered the fundamental hallmark of MET, as it allows 
tumour cells to interact with the bone marrow and adhere to the HSC niche31, 
71. Once in the bone, tumour cells first form micro-metastases that can either 
proliferate and form overt metastatic lesions or remain dormant for long 
periods until reactivate and establish tumours73. The mechanisms by which 
some tumour cells remain dormant whilst others are stimulated to proliferate 
remain to be established. However, amassing evidence suggests that factors 
that increase bone turnover including menopause / ovariectomy may stimulate 
the cells within the mesenchymal stem cell niche and drive proliferation of 
dormant tumour cells74. Increased proliferation of tumour cells in the bone 
marrow causes the production of molecules and growth factors by both 
tumour cells and bone resorption that promote tumour growth, osteoclasts 
production, osteoblasts inactivation and bone destruction (osteolysis), a 
process known as ‘’vicious cycle’’ as shown in figure 373. More specifically, 
proliferating cancer cells have been shown to release factors such as 
parathyroid hormone-related protein (PTHrP), interleukins (IL-8,11), MMP-1, 
cyclooxygenase-2 (COX-2), transcription factor GLI2 and hypoxia-induced 
growth factor 1 α (HIF1α) that promote both their growth in the bone marrow 
and osteolysis.  
PTHrP 
PTHrP is a major regulator of osteolytic lesion formation and a key molecule 
responsible for the humoral hypercalcemia of malignancy75-76. Moreover, 
PTHrP has been shown to be expressed in 92% of primary breast cancers 
that metastasised to bone compared with tumours that metastasised to non-
bone sites (17%) and primary tumours that did not metastasise (60%)77. It is 
hypothesised that release of PTHrP by tumour cells primes the bone 
environment for growth of metastatic tumour cells by increasing bone turnover. 
Release of transforming growth factor-β (TGF-β) from the bone marrow 
increases PTHrP secretion from breast cancer cells via activation of Smad 
and p38 MAP kinase pathways78. This stimulates the production of receptor 
activator of nuclear factor-κB ligand (RANKL) that subsequently binds to 
RANK and induces osteoclast differentiation and activation79. Under normal 
physiological conditions, the binding of RANK to RANKL is homeostatically 
controlled by binding of RANK to it’s decoy receptor, soluble ligand, 
osteoprotegerin (OPG) (Simonet et al., 1997). However, production of PTHrP 
by tumour cells has been shown to inhibit OPG activity thus promoting bone 
metastasis (Chiechi et al., 2013). Breast cancer cells also express 
cyclooxygenase-2 (COX-2) which plays an important role in the development 
of osteolytic bone metastasis by driving over-expression of prostaglandin E2 
(PGE2)80. Moreover, the production of osteolytic factors including IL-8 and IL-
11 by breast cancer cells appear to play an important role in osteoclast 
formation. Bendre and co-workers showed a direct effect of IL-8 in osteoclast 
differentiation and activation leading to the knock on effect of bone 
destruction81. In addition, it was shown that IL-11 mediates bone resorption by 
increasing the osteoblast production of RANKL2. Evidence from IL-11 
overexpressing cell lines indicate that this molecule also has direct effects on 
promoting bone metastasis in vivo82. Similarly to IL-11, MMP-1 promotes 
osteolytic bone metastasis by increasing the osteoblast production of RANKL 
and also by suppressing the expression of osteoprotegerin through activation 
of EGFR-dependent signalling pathway83. Metastatic breast cancer cells often 
express HIF1α that promotes osteoclast formation and inhibit osteoblast 
differentiation (activation)84 as well as transcription factor GLI2 that promote 
the production of PTHrP, facilitating osteolysis85.  
TGF-β 
As a result of bone destruction stimulated by the osteoclast promoting factors 
released from breast cancer cells, growth factors such as TGF-β stored in a 
latent form in bone marrow are released86. The activation of TGF-β signalling 
has been observed in several studies and correlates with breast cancer bone 
metastasis formation87-88. It therefore appears that breaking the vicious cycle 
between tumour growth and bone destruction may be necessary for 
successful treatment of breast cancer bone metastasis. In an attempt to 
address this, a small molecule targeted against the TGF-β receptor 1 has 
been developed. YR-290 blocks TGF-β signalling by inhibiting nuclear 
translocation of Smad 2 and reducing phosphorylation of Smad 2/3. 
Treatment of HaCaT cells with YR-290 inhibits TGF-β-induced EMT, resulting 
in dose-dependent increases in expression of vimentin and fibronectin and in 
increase in E-cadherin. Furthermore, in a 4T1 mouse model, YR-290 blocked 
spontaneous metastasis to lung by 74.71% and 97.38% in groups treated with 
1mg/kg/day and 5mg/kg/day, respectively. Moreover, it has been 
demonstrated that blocking of TGF-β signalling in MDA-MB-231 breast cancer 
cells inhibited the development of osteolytic bone metastases in vivo89. 
Although these data are from early stage experiments they provide an incite 
into the potential therapeutic benefits of targeting EMT/MET to produce noval 
treatments for preventing development and progression of breast cancer bone 
metastasis. 
Conclusions 
The molecular alterations associated with driving breast cancer metastasis to 
bone are still not fully understood, however, it is clear that this involves a vast 
number of molecules leading to large scale functional and architectural 
change of the cancer cell. Metastasis appears to be primarily driven by 
alterations in adhesion complexes and the cytoskeleton enabling the cell to 
firstly escape from the primary tumour and then lodge in its metastatic site. 
The exact chronology of individual changes remains unclear and a number of 
molecular pathways converge to generate an altered phenotype. The switch 
between one phenotype and another is rapid and the exact order in which 
these happen may prove difficult to identify. Furthermore, it is still unclear 
which, if any, of these molecules has the overriding influence on EMT/MET. 
Being a trigger of EMT is a claim common to TGF-β, TWIST, HIF-1α and E-
Cadherin with alterations in the remaining molecules having an effect on EMT 
to differing extents. Redundancy that is typical in biological systems, may 
prove to be problematic when choosing a suitable EMT/MET related target for 
blocking the spread of cancer. However, as seeding of breast cancer cells into 
the bone is an early event it is likely that tumour cells may already be present 
in the bones of patients before they are diagnosed with breast cancer90-91. 
Therefore, molecules associated with early onset of metastasis may provide 
useful biomarkers for predicting disease recurrence. For drug targets, it may 
be more pertinent to identify novel molecules associated with tumour growth 
in bone. 
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 Figure legends 
Figure 1. Breast cancer metastasis is initiated by tumour cell 
dissemination into the circulation. Diagrammatic representation showing 
the molecular alterations that drive phenotypic alterations in cancer cells 
leading to tumour cell dissemination into the blood and lymphatic vesels. 
Figure 2. Molecular pathways involved in epithelial to mesenchymal 
transition. Molecules shown in red are downregulated and molecules shown 
in green are upregulated during epithelial to mesenchymal transition. 
Figure 3. Breast cancer cells home to the bone microenvironment. Bone 
is made up of different cell types that express a variety of molecules including 
the chemokine CXCL12 that attract breast cancer cells to this 
microenvironment. Breast cancer cells also express molecules including the 
chemokine receptor CXCR4 that enable them to adhere to the osteoblast rich 
HSC cell niche and disseminate in the bone. Once in the bone 
microenvironment tumour derived growth factors prime the bone for 
subsequent colonisation of tumour cells. 
Figure 4. Breast cancer cells disseminated in bone colonise this 
environment. Disseminated breast cancer cells in the bone 
microenvironment undergo mesenchymal to epithelial transition enabling 
colonisation and growth at this metastatic site. Tumour cells growing in bone 
secrete growth factors that stimulate osteoclastic bone resorption. This in turn 
result in a vicious cycle whereby osteoclasts release bone derived growth 
factors that further stimulate tumour growth. 
 
 
 
 
 




